EyePoint Pharmaceuticals
11.14.19
EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate DevelopmentSource: EyePoint Pharmaceuticals
11.04.19
EyePoint Pharmaceuticals Announces Addition of Dexycu and Yutiq to Department of Veteran Affairs Federal Supply ScheduleSource: EyePoint Pharmaceuticals
10.02.19
EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for Yutiq Now in EffectSource: EyePoint Pharmaceuticals
09.27.19
EyePoint Pharmaceuticals Announces Yutiq Presentations at AAO Annual MeetingSource: EyePoint Pharmaceuticals
09.09.19
EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at Retina Society Scientific MeetingSource: EyePoint Pharmaceuticals
07.25.19
EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code for YutiqSource: EyePoint Pharmaceuticals
07.08.19
EyePoint Pharmaceuticals Announces US Commercialization of DexycuSource: EyePoint Pharmaceuticals
06.10.19
EyePoint Pharmaceuticals Names New Members of Executive Leadership TeamSource: EyePoint Pharmaceuticals
05.01.19
EyePoint Pharmaceuticals Presents Positive Yutiq 36-Month Follow-Up Phase 3 Data at ARVOSource: EyePoint Pharmaceuticals
03.12.19
EyePoint Pharmaceuticals Announces US Commercial Launch of DexycuSource: EyePoint Pharmaceuticals